SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- CareFusion, a leading, global medical technology company, and Fisher & Paykel Healthcare, a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea, today announced a three-year renewal of their longstanding agreement providing CareFusion the exclusive right to distribute Fisher & Paykel Healthcare products into the U.S. hospital market.
"For more than 25 years, we have partnered with Fisher & Paykel Healthcare to bring its portfolio of clinically differentiated respiratory solutions to U.S. hospitals," said Vivek Jain, president of the Procedural Solutions segment for CareFusion. "As we extend and strengthen our strategic relationships with proven partners like Fisher & Paykel Healthcare, our customers benefit from continued access to market-leading technologies that help improve the cost, quality and safety of patient care."
Under the agreement, CareFusion, through its AirLife™ Respiratory Consumables business, will continue to serve as the exclusive U.S. distributor of Fisher & Paykel Healthcare's extensive portfolio of respiratory consumable products, including the MR850 Heated Humidification System with Evaqua™ circuit technology, AIRVO™ high flow device, Optiflow™ nasal cannula, and FlexiFit™ non-invasive interfaces.
"Through our extended partnership, Fisher & Paykel Healthcare can leverage CareFusion's experience and expertise in the respiratory and acute care markets to continue to grow our business in the United States," said Justin Callahan, president of U.S. operations for Fisher & Paykel Healthcare. "We have been pleased with the strong relationships CareFusion's AirLife team has established with U.S. hospitals and look forward to continuing our longstanding partnership with CareFusion."
About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare (NZSX: FPH, ASX: FPH) is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company's products are sold in more than 120 countries worldwide. For more information about the company, visit www.fphcare.com.
Cautions Concerning Forward-looking Statements
This news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. Forward-looking statements include, but are not limited to, statements about the expected benefits of the distribution agreement between CareFusion and Fisher & Paykel Healthcare, as well as future growth opportunities that may result from this and other relationships between the companies. The forward-looking statements contained herein are based on current expectations and assumptions and not on historical facts, and actual results may differ materially if CareFusion and Fisher & Paykel Healthcare fail to achieve the intended benefits of the agreement. Additional factors that may affect CareFusion's future results are described in its Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports that CareFusion files with the U.S. Securities and Exchange Commission. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.